Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer; Suzanne Lentzsch; Katja Weisel; Herve Avet-Loiseau; Tomer M Mark; Ivan Spicka; Tamas Masszi; Birgitta Lauri; Mark-David Levin; Alberto Bosi; Vania Hungria; Michele Cavo; Je-Jung Lee; Ajay K Nooka; Hang Quach; Cindy Lee; Wolney Barreto; Paolo Corradini; Chang-Ki Min; Emma C Scott; Asher A Chanan-Khan; Noemi Horvath; Marcelo Capra; Meral Beksac; Roberto Ovilla; Jae-Cheol Jo; Ho-Jin Shin; Pieter Sonneveld; David Soong; Tineke Casneuf; Christopher Chiu; Himal Amin; Ming Qi; Piruntha Thiyagarajah; A Kate Sasser; Jordan M Schecter; Maria-Victoria Mateos

Journal article

Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR

Andrew Spencer, Suzanne Lentzsch, Katja Weisel, Herve Avet-Loiseau, Tomer M Mark, Ivan Spicka, Tamas Masszi, Birgitta Lauri, Mark-David Levin, Alberto Bosi, Vania Hungria, Michele Cavo, Je-Jung Lee, Ajay K Nooka, Hang Quach, Cindy Lee, Wolney Barreto, Paolo Corradini, Chang-Ki Min, Emma C Scott Show all

HAEMATOLOGICA | FERRATA STORTI FOUNDATION | Published : 2018

DOI: 10.3324/haematol.2018.194118

Download PDF

University of Melbourne Researchers

Hang Quach Author Medicine - St Vincent's Hospital

Grants

Funding Acknowledgements

This study was sponsored by Janssen Research & Development, LLC. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency.As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.